ERBB2 and breast cancer: To find out whether migration of these human breast cancer cell lines depends on endogenously produced VEGF-C, we used three different approaches, namely (1) the treatment of cells with a VEGF-C neutralising/function blocking antibody, (2) transfection of cells with VEGF-C siRNA to downregulate gene expression, and (3) the treatment of cells with kinase inhibitors for EGFR/Her2/neu PD153035), Src (PPI), and p38 MAPK (SB203580) at non-toxic concentrations which have recently been shown to inhibit VEGF-C production by MDA-MB-231 cells (Timoshenko et al, 2006).